A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Saved in:
Bibliographic Details
Title: A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.
Authors: Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., Thomas A; Duke Cancer Institute, Duke University, Durham, North Carolina, USA., Althouse S; Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA., Zang Y; Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA., Conder E; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., Burgos R; Van Andel Institute, Grand Rapids, Michigan, USA., Schneider BP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., Ballinger T; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., Douglas E; Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Ansley K; Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Jang HJ; Van Andel Institute, Grand Rapids, Michigan, USA., Chung W; Coriell Institute for Medical Research, Camden, New Jersey, USA., Issa JP; Coriell Institute for Medical Research, Camden, New Jersey, USA., Nephew KP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., Rassool FV; University of Maryland School of Medicine, Baltimore, Maryland, USA.
Source: Cancer [Cancer] 2026 Apr 15; Vol. 132 (8), pp. e70407.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70407